Catherine Thieblemont Selected Research

Therapeutics

11/2022	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
2/2022	The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells.
1/2022	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.
1/2022	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
1/2022	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
1/2022	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
1/2022	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
1/2022	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
1/2022	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
1/2022	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Catherine Thieblemont Research Topics

Disease

48	Lymphoma (Lymphomas) 12/2022 - 12/2002
41	Neoplasms (Cancer) 12/2022 - 02/2003
38	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2022 - 09/2009
25	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022 - 10/2005
23	B-Cell Lymphoma (Lymphoma, B Cell) 11/2022 - 03/2005
11	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 01/2004
9	Infections 01/2022 - 02/2012
8	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 08/2010
8	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2022 - 02/2003
7	Disease Progression 01/2022 - 08/2012
6	Hodgkin Disease (Hodgkin's Disease) 11/2016 - 07/2004
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2022 - 04/2004
5	Neutropenia 01/2022 - 05/2013
4	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2022 - 09/2013
3	Multiple Myeloma 06/2022 - 07/2004
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2022 - 03/2005
3	Febrile Neutropenia 01/2022 - 04/2011
3	Cytokine Release Syndrome 11/2021 - 11/2020
3	Cytopenia 08/2014 - 06/2002
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022 - 03/2005
2	Fever (Fevers) 01/2022 - 08/2012
2	COVID-19 12/2021 - 01/2020
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2021 - 11/2015
2	Extranodal NK-T-Cell Lymphoma 01/2021 - 02/2011
2	Residual Neoplasm 11/2020 - 03/2016
2	Fatigue 01/2020 - 01/2019
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2013
2	Tumor Lysis Syndrome 10/2014 - 08/2013
2	Acute Kidney Injury (Acute Renal Failure) 10/2014 - 08/2013
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2022
1	Lymphopenia (Lymphocytopenia) 01/2022

Drug/Important Bio-Agent (IBA)

41	Rituximab (Mabthera)FDA Link 03/2022 - 01/2004
11	Chimeric Antigen ReceptorsIBA 11/2022 - 01/2020
11	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 03/2003
10	obinutuzumabIBA 01/2022 - 05/2012
10	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 03/2003
10	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 03/2003
10	Prednisone (Sone)FDA LinkGeneric 01/2019 - 03/2003
9	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 08/2010
8	ibrutinibIBA 03/2022 - 08/2014
8	Biological ProductsIBA 01/2022 - 02/2012
8	Lenalidomide (CC 5013)FDA Link 01/2022 - 01/2012
6	axicabtagene ciloleucelIBA 11/2022 - 11/2020
6	selinexorIBA 02/2022 - 07/2020
6	Monoclonal AntibodiesIBA 10/2016 - 12/2002
5	Agammaglobulinaemia Tyrosine KinaseIBA 03/2022 - 08/2014
5	Dexamethasone (Maxidex)FDA LinkGeneric 11/2020 - 08/2010
5	Proteins (Proteins, Gene)FDA Link 10/2019 - 04/2011
4	Biomarkers (Surrogate Marker)IBA 12/2022 - 10/2020
4	tisagenlecleucelIBA 01/2022 - 11/2020
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 05/2013
4	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 02/2003
4	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 11/2011
4	Chlorambucil (Leukeran)FDA Link 06/2017 - 03/2003
3	idelalisibIBA 02/2022 - 01/2018
3	Transcription Factors (Transcription Factor)IBA 02/2022 - 01/2020
3	Bendamustine Hydrochloride FDA Link 01/2022 - 02/2017
3	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 12/2015
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 08/2010
3	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 11/2011
3	Immunoglobulins (Immunoglobulin)IBA 12/2018 - 03/2005
3	Pharmaceutical PreparationsIBA 01/2018 - 08/2014
3	Etoposide (VP 16)FDA LinkGeneric 10/2016 - 04/2011
3	Ifosfamide FDA LinkGeneric 10/2016 - 04/2011
3	DNA (Deoxyribonucleic Acid)IBA 07/2015 - 03/2009
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2022 - 01/2021
2	NF-kappa B (NF-kB)IBA 02/2022 - 01/2020
2	Histone Deacetylase InhibitorsIBA 01/2022 - 04/2015
2	Immunoglobulin M (IgM)IBA 01/2022 - 03/2005
2	romidepsin (FK228)FDA Link 01/2022 - 04/2015
2	tocilizumab (atlizumab)FDA Link 11/2021 - 01/2021
2	Methotrexate (Mexate)FDA LinkGeneric 04/2021 - 02/2011
2	Antiviral Agents (Antivirals)IBA 01/2020 - 03/2015
2	Asparaginase (Elspar)FDA Link 01/2019 - 02/2011
2	OTX015IBA 04/2016 - 03/2016
2	Histones (Histone)IBA 01/2016 - 04/2011
2	Bleomycin (Blenoxane)FDA LinkGeneric 12/2014 - 04/2011
2	rasburicase (Elitek)FDA Link 10/2014 - 08/2013
2	tipifarnib (R115777)IBA 03/2010 - 04/2008
2	Farnesyltranstransferase (Farnesyltransferase)IBA 03/2010 - 04/2008
2	AntigensIBA 05/2006 - 04/2005
1	SaltsIBA 03/2022
1	PlatinumIBA 03/2022
1	GlobulinsIBA 01/2022
1	blinatumomabIBA 01/2022
1	atezolizumabIBA 01/2022

Therapy/Procedure

50	Therapeutics 11/2022 - 12/2002
24	Stem Cell Transplantation 06/2022 - 10/2005
18	Drug Therapy (Chemotherapy) 01/2022 - 12/2002
6	Transplantation 01/2022 - 01/2017
5	Splenectomy 12/2018 - 06/2002
4	Radiotherapy 10/2021 - 11/2011
3	Immunotherapy 06/2022 - 12/2018
3	Hematopoietic Stem Cell Transplantation 01/2021 - 08/2012
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 08/2010
2	Induction Chemotherapy 11/2020 - 01/2020
2	Salvage Therapy 11/2011 - 08/2010
1	Blood Component Removal (Apheresis) 01/2022
1	Injections 01/2022
1	Kidney Transplantation 01/2022